Vaccine最新文献

{"title":"A tale of two U.S. Global health security futures—withdraw or evolve?","authors":"Nahid Bhadelia ,&nbsp;Craig Spencer ,&nbsp;Elizabeth Cameron","doi":"10.1016/j.vaccine.2025.127399","DOIUrl":"10.1016/j.vaccine.2025.127399","url":null,"abstract":"<div><div>Rapid detection and response to biological threats are critical to global health security. For decades, the United States has played a leading role in international outbreak response. However, recent U.S. policy shifts, including deep cuts to global health programs, reductions in personnel, and withdrawal from key institutions like the World Health Organization, are weakening disease detection and response systems worldwide. These actions threaten outbreak preparedness, data sharing, research collaboration, and frontline response capabilities, increasing the risk of uncontrolled epidemics with potentially catastrophic consequences.</div><div>Diminished U.S. engagement in global health security has created a critical void, weakening disease surveillance, biosecurity, biosafety, outbreak control, and the development and distribution of medical countermeasures. The erosion of American leadership undermines global capacity to detect and respond to emerging threats, increasing the risk of epidemics and pandemics. Rather than retreating, the United States must sustain and strengthen its global health programs, integrating efforts to enhance efficiency and effectiveness, to safeguard both international stability and American pandemic preparedness.</div></div>","PeriodicalId":23491,"journal":{"name":"Vaccine","volume":"61 ","pages":"Article 127399"},"PeriodicalIF":4.5,"publicationDate":"2025-06-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144314532","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Chimeric designs of rabies virus glycoprotein G enhance baculovirus pseudotyping and immunogenicity in mice: influence of the transmembrane domain and a flexible linker","authors":"Ricardo Choque-Guevara ,&nbsp;Astrid Poma-Acevedo ,&nbsp;Ricardo Montesinos-Millán ,&nbsp;Yacory Sernaque-Aguilar ,&nbsp;Freddy Ygnacio ,&nbsp;Dora Ríos-Matos ,&nbsp;Ángela Montalván-Ávalos ,&nbsp;Gisela Isasi-Rivas ,&nbsp;Milagros Lulo ,&nbsp;Roque Fernández-Vera ,&nbsp;Julio Ticona ,&nbsp;Manolo Fernández-Sánchez ,&nbsp;Manolo Fernández-Díaz","doi":"10.1016/j.vaccine.2025.127404","DOIUrl":"10.1016/j.vaccine.2025.127404","url":null,"abstract":"<div><div>Rabies remains a lethal zoonotic disease, affecting approximately 50,000 people annually, underscoring the need for new and cost-effective vaccines capable of elicit robust immunity. Baculoviruses have emerged as promising vaccine vectors due to their ability to display antigens on their surface, making pseudotyping with rabies virus glycoprotein G (gG) a viable strategy for vaccine development. However, strategies to optimize baculovirus pseudotyping remain underexplored. In this study, we evaluated three chimeric gG designs and found that fusion to the gp64 transmembrane domain via a flexible linker significantly enhanced both baculovirus pseudotyping and the resulting immune response. The chimeras consisted of the gG ectodomain fused to the gp64 transmembrane domain either directly (gG-AN) or via a flexible linker (gG-FL), along with a variant retaining its native transmembrane domain (gG-TM). Notably, baculoviruses pseudotyped with gG-FL and gG-AN achieved the highest levels of gG incorporation into viral particles, while gG-TM impaired baculovirus replication. All pseudotyped baculoviruses elicited neutralizing antibodies against rabies virus; however, gG-FL induced the strongest immune response, as evidenced by full activation of bone marrow-derived dendritic cell markers, higher neutralizing antibody titers, and increased IFN-γ production. This enhanced immunogenicity correlated with greater protection following rabies virus challenge, with gG-FL baculovirus-immunized mice achieving the highest survival rates. Moreover, an adjuvanted gG-FL formulation showed an immunological potency of 4.65 IU/dose. These findings highlight the importance of transmembrane domain selection and flexible linker incorporation in optimizing baculovirus pseudotyping with gG and enhancing its immunogenicity against rabies virus. This strategy could inform the design of future baculovirus-based vaccines.</div></div>","PeriodicalId":23491,"journal":{"name":"Vaccine","volume":"61 ","pages":"Article 127404"},"PeriodicalIF":4.5,"publicationDate":"2025-06-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144314523","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Designing effectiveness and impact studies for respiratory syncytial virus immunisation in low- and middle-income countries","authors":"Rita Reyburn ,&nbsp;Fiona M. Russell ,&nbsp;Patrick K. Munywoki ,&nbsp;Lauren Franzel ,&nbsp;Tran T.G. Huong ,&nbsp;Daniel Feikin ,&nbsp;Louis J. Bont","doi":"10.1016/j.vaccine.2025.127397","DOIUrl":"10.1016/j.vaccine.2025.127397","url":null,"abstract":"<div><div>Respiratory syncytial virus (RSV) is a leading cause of childhood pneumonia and 97 % of the estimated 100,000 annual deaths globally, occur in low and middle-income countries (LMICs). An increasing number of immunisation strategies are being developed. However, there is increasing awareness that much of the evidence of the efficacy and effectiveness of RSV immunisations is derived from high-income countries, while results may not accurately extrapolate to LMICs. There is thus an urgent need for carefully planned post-licensure studies that are appropriate to the widely differing conditions in LMICs. We outline immunisation evaluation study designs with scenario-based options for evaluating RSV immunisations in LMICs and summarize high-level recommendations for their use. The case-control test-negative study design is likely to be most suited to estimate immunisation effectiveness in LMIC settings and a pre-vs-post immunisation study design will allow a measure of immunisation impact following the introduction of RSV immunisation.</div></div>","PeriodicalId":23491,"journal":{"name":"Vaccine","volume":"61 ","pages":"Article 127397"},"PeriodicalIF":4.5,"publicationDate":"2025-06-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144314508","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Drivers of HPV vaccine hesitancy in New York and Florida","authors":"Kaitlin (Quirk) Brumbaugh ,&nbsp;Alex de Figueiredo ,&nbsp;Frances R. Gellert ,&nbsp;Francisco Rios Casas ,&nbsp;Tara McCoy ,&nbsp;Heidi J. Larson ,&nbsp;Ali H. Mokdad","doi":"10.1016/j.vaccine.2025.127395","DOIUrl":"10.1016/j.vaccine.2025.127395","url":null,"abstract":"<div><h3>Background</h3><div>This study aimed to identify drivers of HPV vaccine hesitancy and effective public health interventions to increase HPV vaccination rates in two U.S. states (New York and Florida) and 12 counties within each state. The findings provide insights into the impact of demographics, state policies, and vaccine confidence on HPV vaccination.</div></div><div><h3>Methods</h3><div>We utilized a mixed-method approach, integrating quantitative analysis of county-level surveys, qualitative interviews, and secondary data on HPV vaccine coverage. Surveys, adapted from the Vaccine Confidence Project (VCP) and the World Health Organization (WHO), assessed HPV vaccine confidence, socio-demographics, and behavioral determinants. Interviews explored barriers, interventions, and policies related to HPV vaccination.</div></div><div><h3>Findings</h3><div>Parents and providers have not prioritized HPV vaccination compared to other vaccines, with less concern about HPV than other vaccine-preventable diseases. Socio-demographic factors, such as race, age, gender, religion, employment, and income impacted children's vaccination status. Female parents aged 35–44 and those with a professional degree were more likely to vaccinate their children. Perceptions of the vaccine's importance and safety significantly influenced vaccination.</div></div><div><h3>Interpretation</h3><div>Identifying socio-demographic determinants and behavioral motivators can guide targeted interventions. Our study highlights complex factors influencing HPV vaccination at the state and county level, offering policymakers strategies to tailor interventions addressing barriers and hesitancy in areas with lower vaccination rates.</div></div>","PeriodicalId":23491,"journal":{"name":"Vaccine","volume":"61 ","pages":"Article 127395"},"PeriodicalIF":4.5,"publicationDate":"2025-06-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144314525","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Immunologic responses to an extracellular vesicle-based vaccine expressing the full suite of SARS-CoV-2 structural proteins","authors":"Tamanna Mustajab ,&nbsp;Moriasi Sheba Kwamboka ,&nbsp;Imran Khan ,&nbsp;Dajung Song ,&nbsp;Sorim Lee ,&nbsp;Kyu Ri Han ,&nbsp;Yujin Han ,&nbsp;Jaeyoung Kim ,&nbsp;Yong-Joon Chwae","doi":"10.1016/j.vaccine.2025.127407","DOIUrl":"10.1016/j.vaccine.2025.127407","url":null,"abstract":"<div><div>In an attempt to develop a novel extracellular vesicles (EVs)-based vaccine against COVID-19, we designed EVs harboring a full set of SARS-CoV-2 structural proteins. Thus, the receptor-binding domain (RBD) of spike protein (S) of SARS-CoV-2 variant BA.2 or BA.4/5 with the stabilized wild type spike protein backbone, nucleocapsid protein (N) C-terminally fused with CD63, membrane (M), and envelope (E) proteins were stably expressed in 293T cells. Then, cell death-associated EVs were collected from the cells and evaluated for the expression of SARS-CoV-2 structural proteins. As a result, it was confirmed that trimers of spike fusion protein, N, M, and E were successfully loaded in the EVs. In an intramuscular injection model of mice, the inoculation of 50 μg EVs resulted in significant IgG antibody responses to S after the booster injection and neutralized the entry of S-pseudotyped VSVs. Anti-nucleocapsid antibodies were efficiently increased in mice primarily injected with 25 or 50 μg EVs, showing further increased values after booster dosages. Memory CD4⁺ T_H1 cells and CD8⁺ T_C cells against S and N proteins was generated in mice that received a booster-immunization with all dosages (10, 25, or 50 μg) of EVs. Additionally, T cells responses against M and E peptides were increased in booster-immunized mice that received 50 μg of EVs. Taken together, this work proved feasibility of EVs expressing SARS-CoV-2 proteins as a universal vaccine candidate, potentially offering protection against emerging SARS-CoV-2 variants and future pandemics.</div></div>","PeriodicalId":23491,"journal":{"name":"Vaccine","volume":"61 ","pages":"Article 127407"},"PeriodicalIF":4.5,"publicationDate":"2025-06-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144306834","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Safety, immunogenicity, and breakthrough infection of nine homologous or heterologous COVID-19 vaccination booster regimens in healthy adults: A prospective study in Taiwan","authors":"Wen-Pin Tseng ,&nbsp;Jhong-Lin Wu ,&nbsp;Chien-Hao Lin ,&nbsp;Chun-Min Kang ,&nbsp;Ming-Yi Chung ,&nbsp;Ya-Fan Lee ,&nbsp;Shey-Ying Chen ,&nbsp;Min-Chi Lu ,&nbsp;Wen-Chien Ko ,&nbsp;Ping-Ing Lee ,&nbsp;Po-Ren Hsueh","doi":"10.1016/j.vaccine.2025.127383","DOIUrl":"10.1016/j.vaccine.2025.127383","url":null,"abstract":"<div><h3>Background</h3><div>The COVID-19 pandemic necessitated diverse vaccination strategies to enhance immune protection. This study aimed to evaluate the immunogenicity, reactogenicity, and breakthrough infection of nine distinct vaccination regimens involving homologous or heterologous second booster doses in a SARS-CoV-2-naïve population in Taiwan.</div></div><div><h3>Methods</h3><div>From December 2021 to May 2022, 784 healthy adults who had completed either homologous or heterologous prime and first booster vaccinations received a second booster dose, resulting in nine vaccination combinations. Reactogenicity was monitored for seven days post-vaccination. Immunogenicity was assessed using Roche and Abbott anti-spike antibody assays and a surrogate virus neutralization test (sVNT) at baseline, one month, and six months post-booster. Breakthrough infections during a six-month follow-up period were recorded to evaluate vaccine performance.</div></div><div><h3>Results</h3><div>All regimens significantly boosted humoral immune responses at one month post-second booster. The homologous mRNA-1273 (MMM) group exhibited the highest antibody levels, despite participants having older age and more comorbidities. Antibody levels declined at six months across all groups, but the MMM group consistently maintained the highest levels. The protein subunit vaccine MVC-COV1901 induced lower antibody levels but demonstrated a favorable reactogenicity profile, with fewer systemic adverse events. Breakthrough infection rates varied among groups, with comparable infection risks observed in participants receiving mRNA-1273 or MVC-COV1901 boosters following a homologous ChAdOx1 primary vaccination. No severe infections, hospitalizations, or deaths were reported.</div></div><div><h3>Conclusions</h3><div>Homologous and heterologous COVID-19 booster regimens are safe and effective, with mRNA-1273 providing the strongest humoral immunity. These findings support tailored booster strategies to maintain population immunity and manage the pandemic.</div></div>","PeriodicalId":23491,"journal":{"name":"Vaccine","volume":"61 ","pages":"Article 127383"},"PeriodicalIF":4.5,"publicationDate":"2025-06-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144306885","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Accelerating development of vaccines for prevention and control of Alzheimer's disease","authors":"Wayne C. Koff ,&nbsp;David M. Holtzman","doi":"10.1016/j.vaccine.2025.127410","DOIUrl":"10.1016/j.vaccine.2025.127410","url":null,"abstract":"","PeriodicalId":23491,"journal":{"name":"Vaccine","volume":"61 ","pages":"Article 127410"},"PeriodicalIF":4.5,"publicationDate":"2025-06-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144314504","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Attitudes towards conventional and non-conventional medical approaches and their relation to COVID-19 vaccination: Insights from Germany","authors":"Alexander Patzina ,&nbsp;Miriam Trübner ,&nbsp;Judith Lehmann ,&nbsp;Benno Brinkhaus ,&nbsp;Christian S. Kessler ,&nbsp;Rasmus Hoffmann","doi":"10.1016/j.vaccine.2025.127403","DOIUrl":"10.1016/j.vaccine.2025.127403","url":null,"abstract":"<div><div>The main objective of this study is to investigate whether different medical attitudes relate to COVID-19 vaccination uptake and approval of vaccine mandates. The theory of planned behavior and the health belief model suggest that individual attitudes towards medical approaches are important for vaccination uptake. We use data from a German online cross-sectional study comprising 4065 respondents conducted between September and October in 2022 on the use and acceptance of five pre-defined medical approaches: conventional medicine, Traditional European Medicine (<em>Naturheilkunde</em>), complementary medicine, integrative medicine, and alternative medicine. The two main outcome measures are: (1) COVID-19 vaccination uptake, differentiating between (a) rejected, (b) socially pressured and (c) endorsed vaccination; (2) attitudes towards mandatory COVID-19 vaccination, i.e., whether or not individuals endorse vaccination mandates. We employ logistic and multinomial logistic regressions to calculate average marginal effects (AME) and to account for the influence of different medical attitudes and for confounding variables. While vaccination uptake in general is high (91.0 % in the analytical sample), our multivariate results reveal that individuals with a positive disposition towards Traditional European Medicine (AME = 0.05; <em>p</em> &lt; 0.01) and alternative medicine (AME = 0.02; <em>p</em> &lt; 0.10) were, comparatively, more likely to reject COVID-19 vaccination. A positive disposition towards conventional medicine is associated with higher vaccination uptake (AME = 0.17; <em>p</em> &lt; 0.001). Positive attitudes towards alternative medicine correlate with increased levels of feeling socially pressured into accepting the vaccination (AME = 0.05; <em>p</em> &lt; 0.01). Approval levels for universal mandatory vaccination are low (43.9 %). Positive attitudes towards alternative (AME = -0.03; <em>p</em> &lt; 0.1) and Traditional European Medicine (AME = -0.04; <em>p</em> &lt; 0.05) negatively correlate with approval of vaccination mandates, while positive attitudes towards conventional medicine (AME = 0.05; <em>p</em> &lt; 0.01) increase approval. Our findings suggest that different medical attitudes are simultaneously associated with vaccination uptake and mandate approval. This provides important knowledge for policy makers when designing vaccination schemes and for health professionals when consulting their heterogeneous group of patients.</div></div>","PeriodicalId":23491,"journal":{"name":"Vaccine","volume":"61 ","pages":"Article 127403"},"PeriodicalIF":4.5,"publicationDate":"2025-06-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144314524","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Development of an efficacious oral peptide vaccine against infection with the carcinogenic liver fluke Opisthorchis viverrini","authors":"Wuttipong Phumrattanaprapin ,&nbsp;Ahmed O. Shalash ,&nbsp;Mariusz Skwarczynski ,&nbsp;Michael J. Smout ,&nbsp;Thewarach Laha ,&nbsp;Istvan Toth ,&nbsp;Alex Loukas","doi":"10.1016/j.vaccine.2025.127400","DOIUrl":"10.1016/j.vaccine.2025.127400","url":null,"abstract":"<div><h3>Objectives</h3><div>Chronic <em>Opisthorchis viverrini</em> infection is a major contributor to cholangiocarcinoma in Southeast Asia, necessitating effective vaccine development. This study aimed to evaluate the immunogenicity and protective efficacy of peptide-based oral vaccines targeting <em>O. viverrini</em> in a hamster model.</div></div><div><h3>Methods</h3><div>Five protein fragments from the vaccine candidate antigen <em>Ov</em>-TSP-2 were synthesized, with LEL4 and SEL peptides identified as the most immunogenic. These peptides were conjugated to polymethylacrylate (PMA) for nanoparticle self-assembly and mucosal immunization. Hamsters received four oral immunizations and were challenged with <em>O. viverrini</em> metacercariae to assess immune response and protection.</div></div><div><h3>Results</h3><div>LEL4-immunized hamsters demonstrated elevated antigen-specific serum IgG, mucosal IgG, and IgA titers. This immune response correlated with significantly reduced egg counts and worm burdens. Recovered worms from vaccinated hamsters exhibited stunted growth, indicating impaired parasite development.</div></div><div><h3>Conclusions</h3><div>This study establishes the potential of LEL4 as a peptide-based oral vaccine against <em>O. viverrini</em>. By inducing mucosal and systemic immunity, the vaccine offers a promising strategy for combating opisthorchiasis and its associated cancer risk, marking a significant advancement in liver fluke control.</div></div>","PeriodicalId":23491,"journal":{"name":"Vaccine","volume":"61 ","pages":"Article 127400"},"PeriodicalIF":4.5,"publicationDate":"2025-06-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144298347","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Genetic markers of enhanced functional antibody responses to COVID-19 vaccination","authors":"Ruth A. Purcell ,&nbsp;L. Carissa Aurelia ,&nbsp;Lilith F. Allen ,&nbsp;Katherine A. Bond ,&nbsp;Deborah A. Williamson ,&nbsp;Janine M. Trevillyan ,&nbsp;Jason A. Trubiano ,&nbsp;Bruce D. Wines ,&nbsp;P. Mark Hogarth ,&nbsp;Jennifer A. Juno ,&nbsp;Adam K. Wheatley ,&nbsp;Thi H.O. Nguyen ,&nbsp;Kanta Subbarao ,&nbsp;Katherine Kedzierska ,&nbsp;Stephen J. Kent ,&nbsp;Siddhartha Mahanty ,&nbsp;Kevin John Selva ,&nbsp;Amy W. Chung","doi":"10.1016/j.vaccine.2025.127379","DOIUrl":"10.1016/j.vaccine.2025.127379","url":null,"abstract":"<div><h3>Introduction</h3><div>Substantial population-level variation in vaccine-specific antibody responses has been observed following global coronavirus disease 2019 (COVID-19) vaccination efforts. Beyond the influence of clinical and demographic features, immunogenetic variation is suggested to underlie divergent serological responses following COVID-19 vaccination of distinct populations.</div></div><div><h3>Methods</h3><div>Immunoglobulin G1 (IgG1) allotypic markers (G1m) for 121 COVID-19 vaccinated healthy adults were genotyped via Sanger sequencing. Vaccine-specific IgG and Fc gamma receptor (FcγR) engagement were characterised via bead-based multiplex array.</div></div><div><h3>Results</h3><div>Following two COVID-19 vaccine doses, G1m1,17^+/+ compared to G1m-1,3^+/+ vaccinees had increased IgG and FcγR engagement specific for the antigenically conserved SARS-CoV-2 Spike 2 (S2) domain. IgG targeting antigenically novel SARS-CoV-2 receptor binding domain (RBD) trended higher in G1m1,17^+/+ vaccinees, facilitating increased RBD-specific FcγR2a-R131 and FcγR2b binding.</div></div><div><h3>Conclusion</h3><div>Primary COVID-19 vaccination induced increased S2-specific IgG in G1m1,17^+/+ vaccinees, facilitating enhanced anti-viral FcγR engagement and suggesting immunogenetics may be a valuble consideration for next-generation vaccine design.</div></div>","PeriodicalId":23491,"journal":{"name":"Vaccine","volume":"61 ","pages":"Article 127379"},"PeriodicalIF":4.5,"publicationDate":"2025-06-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144290697","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}